1. 诺华BTK抑制剂「瑞米布替尼」在华申报上市 2月27日，CDE官网显示，诺华BTK抑制剂瑞米布替尼片（remibrutinib）率先在华申报上市。根据临床试验进展以及财报信息，推测此次申报的适应症为慢性自发性荨麻疹。Remibrutinib是一种新型、口服共价不可逆BTK抑制剂，具有非常高的选择性，可快速结合无活性的BTK构象，从而阻止引起瘙痒、荨麻疹/皮疹和肿胀的组胺释放，没有结合的药物则会从体内清除，减少全身暴露，降低毒副作用。2023年，remibrutinib用于CSU的III期REMIX-1和REMIX-2两项研究均取得积极结果，达到所有主要终点和次要终点。 2. 皮尔法伯BRAF+MEK癌症靶向组合疗法在中国申报上市 2月27日，CDE官网公示，皮尔法伯（Pierre Fabre）申报的恩考芬尼胶囊和比美替尼片的上市申请获得受理。恩考芬尼（encorafenib，Braftovi）是一种口服小分子BRAF激酶抑制剂，比美替尼（binimetinib，Mektovi）是一种强效且具有选择性的MEK抑制剂。二者组合疗法此前已经获美国FDA和欧盟委员会批准，用于治疗带有BR

Protein arginine methyltransferases (PRMTs) are catalytic enzymes for arginine methylation, capable of methylating a variety of proteins and playing pivotal roles in biological processes such as gene expression, splicing, and DNA damage repair. Currently, 9 members of the PRMTs family has been identified, divided into three major types. Type I, catalyzes the formation of asymmetric dimethylarginine and includes PRMT1, PRMT2, PRMT3, PRMT4, PRMT6, PRMT8. Type II catalyzes the formation of symmet

CYP2C9 is a member of the Cytochrome P450 superfamily of enzymes that primarily metabolize drugs in the human body. It predominantly occurs in the liver and intestine. Approximately 16% of clinically used drugs are metabolized through it, including anti-diabetic drugs such as tolbutamide, glibenclamide, and glimepiride; anti-epileptic drugs like phenytoin; anticoagulants such as warfarin, disulfiram, nitrophenylbenzene, and propylbenzene; antihypertensives like losartan and irbesartan; diuretics

The conventional treatment for multiple myeloma comprises three main pillars: immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide), proteasome inhibitors (bortezomib, ixazomib, carfilzomib), and monoclonal antibodies (daratumumab, isatuximab, elotuzumab, etc.). Additionally, there are several new drugs undergoing research, such as bispecific antibodies, antibody-drug conjugates (ADCs), Selective Inhibitors of Nuclear Export (XPO1), etc. Currently, CAR-T therapy has promising potentia

PARP, or Poly (ADP-ribose) polymerase, is a type of single-strand DNA repair enzyme that plays a critical role in DNA damage repair and maintaining genome stability. The PARP family includes several members, amongst which only PARP1, PARP2 and PARP3 are involved in DNA repair. PARP1 is the most prominent member of the PARP family, accounting for 80%-90% of the enzyme activity, and is a key player in DNA damage repair. BRCA1/2 are two suppressor genes discovered early on, playing a significant r

The CYP2D6 gene encodes the CYP2D6 enzyme, which is a crucial member of the cytochrome P450 system, a crucial enzyme in the metabolism of various drugs. The CYP2D6 enzyme in humans is mainly expressed in the liver, but is also present in the central nervous system, followed by the myocardium and small intestine. Although it represents only 2% content in the liver, it participates in the metabolism of as many as 25% of commonly used clinical drugs, including antidepressants, antipsychotics, antih

永生化DC-CTL技术是一项细胞免疫治疗领域的创新技术，目前正在中国人民解放军总医院开展临床研究。这是该技术全球首次进行临床研究，截至目前已完成了第一阶段安全性试验，部分患者生存质量QOL评分有所提高。有效性研究还在进展之中。 记者采访了在纽约州立大学Albany分校获得分子生物学博士的邵永平教授，并获悉了新技术永生化DC-CTL技术的最新进展。 邵教授目前是北京惠大生物科技有限公司（简称：惠大生物）首席科学家，曾参与十余项国内外的重大课题研究，在Cancer Ressearch、Immunity等核心期刊发表论文近四十篇，并参与了普通高等教育“十三五”规划教材《分子细胞生物学》的编写。 据了解，永生化DC-CTL技术突破了多年来困扰免疫学发展和免疫细胞抗癌技术的瓶颈，有望彻底攻克癌症。该技术在应对乙肝、艾滋病、禽流感以及中东呼吸综合征等疾病方面也有广阔应用前景。 通过使用与患者HLA相符、表达实体瘤特异性抗原或新抗原的永生化DC细胞株体外激活患者T细胞，使其进行大量扩增并激活成为以特异性CD8+T细胞为主的细胞毒性淋巴细胞（CTLs），针对肿瘤进行特异性杀伤。 永生化DC-CTL技术

IL-23, or Interleukin-23, is a crucial cytokine that plays a significant role in the human body's immune response. It is primarily produced by activated antigen-presenting cells, such as dendritic cells and macrophages. IL-23 acts as a mediator between innate and adaptive immunity by stimulating the production of pro-inflammatory cytokines and promoting the differentiation and expansion of T-helper 17 (Th17) cells. Th17 cells, in turn, produce various cytokines that contribute to inflammation an

Interleukin-1 receptor-associated kinases (IRAKs) were initially identified as serine/threonine kinases that can bind to the interleukin-1 receptor (IL-1R) upon induction by the pro-inflammatory cytokine interleukin-1 (IL-1). Later, these proteins were found to have high homology with the pelle kinases vital for resisting microbial infection in Drosophila Toll-like receptor (TLR) pathways. There are four members in the IRAK family: IRAK1, IRAK2, IRAK 4, and IRAK–M. All four IRAKs have a kinase d

IL-17A, or Interleukin-17A, is a cytokine that plays a crucial role in the human body's immune response. It is primarily produced by T-helper 17 (Th17) cells and other immune cells. IL-17A acts as a pro-inflammatory mediator, promoting the recruitment and activation of immune cells to sites of infection or tissue damage. It is involved in various autoimmune and inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Understanding the role of IL-17A has l